首页> 美国卫生研究院文献>Toxicological Research >Four-Week Repeated Oral Toxicity Study of AIP1 a Water-soluble Carbohydrate Fraction from Artemisia iwayomogi in Mice
【2h】

Four-Week Repeated Oral Toxicity Study of AIP1 a Water-soluble Carbohydrate Fraction from Artemisia iwayomogi in Mice

机译:鼠艾蒿的水溶性碳水化合物组分AIP1在小鼠中的四周重复口服毒性研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Artemisia iwayomogi, a member of the Compositae, is a perennial herb easily found in Korea and used as a traditional medicine to treat liver disease. AIP1, a water-soluble carbohydrate fraction from Artemisia iwayomogi, showed anti-tumor and immuno-modulating activities in animal studies. A subacute toxicological evaluation of AIP1 was performed for 4 weeks in ICR mice. After administration of AIP1 (0, 20, 100, 500 mg/kg/day), the clinical signs, mortalities, body weight changes, hematology, blood clinical biochemistry, urinalysis, organ histopathology, organ weights and gross finding were examined. The results showed that there were no significant differences in body weight changes, food intakes, water consumptions, or organ weights among different dose groups. Also we observed no death and abnormal clinical signs during the experimental period. Between the groups orally treated with AIP1 and the control group, there was no statistical significance in hematological test or serum biochemical values. Histopathological examination showed no abnormal changes in AIP1 groups. These results suggest that no observed adverse effect level (NOAEL) of the oral administration of AIP1 for 4 weeks was considered to be more than 500 mg/kg/ day in mice under the condition investigated in current study.
机译:菊科艾蒿(Artemisia iwayomogi)是菊科的一员,是一种多年生草本植物,在韩国很容易找到,被用作治疗肝病的传统药物。 AIP1是一种来自艾蒿的水溶性碳水化合物馏分,在动物研究中显示出抗肿瘤和免疫调节活性。在ICR小鼠中进行了AIP1的亚急性毒理学评估,为期4周。给予AIP1(0、20、100、500 mg / kg / day)后,检查其临床体征,死亡率,体重变化,血液学,血液临床生化,尿液分析,器官组织病理学,器官重量和总体发现。结果表明,不同剂量组之间的体重变化,食物摄入,水消耗或器官重量没有显着差异。此外,我们在实验期间没有观察到死亡和异常的临床体征。在口服AIP1的组与对照组之间,血液学检查或血清生化值无统计学意义。组织病理学检查显示AIP1组无异常变化。这些结果表明,在当前研究条件下,在小鼠中口服AIP1 4周观察到的不良反应水平(NOAEL)被认为不超过500 mg / kg /天。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号